CARLSBAD, Calif.--(BUSINESS WIRE)--Aug. 10, 2006-- Funding Will Support Continuation of Phase II Clinical Trials In Multiple Sclerosis and HIV. The Immune Response Corporation (OTCBB:IMNR), an immuno-pharmaceutical company developing products to treat autoimmune and infectious diseases, announced it has raised $9.9 million in gross proceeds from investors exercising 495,552,100 warrants from the first tranche warrants that were issued in the Company’s March 2006 private placement financing.
